HSM Helius Medical Technologies Inc

Helius Medical Technologies Announces Reverse Stock Split

Helius Medical Technologies Announces Reverse Stock Split

NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025. Beginning on May 2, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis.

At the Company’s annual meeting of stockholders on April 21, 2025, the stockholders approved a proposal to amend the Company’s Certificate of Incorporation to effect a reverse split of the Company’s outstanding common stock at a ratio in the range of 1-for-2 to 1-for-30 to be determined at the discretion of our Board of Directors, whereby each outstanding 2 to 30 shares would be combined, converted and changed into 1 share of common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements. Subsequently, the Board of Directors approved the reverse split at a ratio of 1-for-15. As a result of the reverse stock split, every 15 shares of the company's common stock issued and outstanding will be automatically converted into one share of common stock, with no change in the $0.001 par value per share or authorized number of shares of common stock.

Upon effectiveness, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company’s outstanding stock options and warrants in proportion to the ratio of the reverse split and will cause a proportionate increase in the conversion and exercise prices of such stock options and warrants. Any fraction of a share of common stock that would be created as a result of the Reverse Stock Split will be rounded down to the next whole share and the stockholder will receive cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company’s common stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis).

The Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “HSDT.” The new CUSIP number for the common stock following the reverse split is 42328V 884.

The number of authorized shares of the Company’s common stock will remain at 150 million, while the number of outstanding shares will be reduced from approximately 7.9 million to approximately 0.5 million.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 25, 2025, a copy of which is also available on the Company’s website under the Investor Relations page.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit .

Investor Relations Contact:

Philip Trip Taylor

Gilmartin Group 

 



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE

Helius to Spotlight Study Confirming Improved Long-Term Outcomes from ...

Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting Shepherd Center’s Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained ef...

 PRESS RELEASE

Helius Medical Technologies, Inc. Announces Reimbursement by Major Hea...

Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement NEWTOWN, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for improving balance and gait deficits and reducing the risk of falling, ...

 PRESS RELEASE

Helius Medical Technologies Announces Reverse Stock Split

Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025. Beginning on May 2, 2025, the Company’s common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company’...

 PRESS RELEASE

Helius Medical Technologies, Inc. Announces the Establishment of a Who...

Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary --Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius’ existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development-- --Helius to Present at the 37th Annual ROTH Conference on Monday, March 17 at 12:00pm PT-- NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasd...

 PRESS RELEASE

Helius Medical Technologies, Inc. Announces First Reimbursement by A M...

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device --Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced its first reimbursement paym...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch